Hemostasis & Tissue Sealing Agents Market Competitive Market Share & Forecast, 2017-2025
![]() |
Hemostasis & Tissue Sealing Agents Market |
Hemostasis is a physiological
process that preserves blood fluidity by limiting blood loss from the body.
Clots form during hemostasis as a result of the natural coagulation cascade
being activated. However, excessive blood loss that results from major surgery
or trauma cannot be stopped by the body's normal healing mechanisms. Hemostats
and tissue sealing agents help in such circumstances by reducing blood loss and
promoting wound healing. In order to reduce the risk associated with excessive
bleeding during surgical procedures, hemostats and tissue sealing agents are
being used more frequently.
Additionally, excessive bleeding
can lead to postoperative complications such as drawn-out surgeries and
insufficient blood levels in the body. Blood loss may be the cause of up to 31%
of fatalities in trauma and catastrophic accident patients in the United
States, according to In-Patient Epidemiology, a statistical study conducted by
the Department of Surgery, Division of Acute Care and Trauma Surgery, New York
University, in 2012. Therefore, avoiding such occurrences is crucial for the
success of surgical procedures and for the good health of patients. Topical
hemostats, such as mechanical hemostats, active hemostats, and Flowable
hemostats—solutions applied topically directly to the bleeding site—along with
natural and artificial tissue sealants serve as an adjunct to the body's normal
hemostasis process and are used locally to control bleeding.
The Global
Hemostasis & Tissue Sealing Agents Market Was Valued At US$
3,236.2 Million In 2017 And Is Expected To Witness A Robust CAGR Of 8.1% Over
The Forecast Period (2017–2025).
The market for hemostasis and
tissue sealing agents is anticipated to grow significantly as a result of
factors like the rising number of surgeries and auto accidents. For instance,
according to the Health and Social Care Information Centre (HSCIC), surgery
accounted for 4.7 million admissions across various sectors in 2013–14, making
it one of the most significant treatments provided by NHS care in the U.K. The
data also suggests that, between 2004 and 2014, there was a 27% increase in
surgical procedures. The Centers for Disease Control and Prevention (CDC)
estimate that about 200,000 Americans died in 2014 as a result of trauma
injuries. A significant contributor to the rise in traumatic sports injuries is
the frequency of increasing road accidents.
Over 50% of those harmed in auto
accidents in 2016 were hospitalised and underwent trauma surgery, according to
the World Health Organization. Due to the larger incisions made on the
patient's body during trauma surgeries and other common procedures like hernia
repair, orthopaedic, open heart and cardiovascular surgery, and neurosurgery
that result in significant blood loss, hemostats are also used in these
procedures. A total of 427,181 procedures were reported for joint replacement
surgeries in 2016, according to the American Joint Replacement Registry's
(AJRR) annual report. However, it is anticipated that the lack of favourable
reimbursement policies for hemostats' failure to control blood loss as well as
the rising cost of surgical procedures will restrain market expansion.
Top Companies involved are- Cryolife, Inc. Baxter International,
Inc., Ethicon LLC, Integra Lifesciences Corporation, Becton, Dickinson &
Company, Cohera Medical, Inc., Pfizer, Inc., Medtronic plc, B. Braun Melsungen
AG, MIL Laboratories Pvt. Ltd, Advanced Medical Solutions Group Plc, and
others.
Comments
Post a Comment